Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Change in Receivables (2021)

Unicycive Therapeutics posted quarterly Change in Receivables of $20000.0 for Q3 2021, down 28.57% on a QoQ basis from $28000.0 in Q2 2021.

Unicycive Therapeutics (UNCY) has 1 years of Change in Receivables data on file, last reported at $20000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 Unicycive Therapeutics 181.94 Mn 127.36 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 20,000.00
Sep 30, 2021 20,000.00
Jun 30, 2021 28,000.00
Jun 30, 2021 28,000.00
Mar 31, 2021 10,000.00
Mar 31, 2021 10,000.00